One-step synthesis of heteroaromatic-fused pyrrolidines via cyclopropane ring-opening reaction: Application to the PKCβ inhibitor JTT-010

Organic Letters

Volumn 9, Issue 17, 2007, Pages 3331-3334

  Tanaka, Masahiro ^a   Ubukata, Minoru ^a   Matsuo, Takafumi ^a   Yasue, Katsutaka ^a   Matsumoto, Katsuya ^a   Kajimoto, Yasuyuki ^a   Ogo, Takashi ^a   Inaba, Takashi ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(2R) 3 (2 AMINOMETHYL 2,3 DIHYDRO 1H 3A AZACYCLOPENTA(A)INDEN 8 YL) 4 PHENYLAMINOPYRROLE 2,5 DIONE MONOMETHANESULPHONATE; (2R)-3-(2-AMINOMETHYL-2,3-DIHYDRO-1H-3A-AZACYCLOPENTA(A)INDEN-8-YL)-4-PHENYLAMINOPYRROLE-2,5-DIONE MONOMETHANESULPHONATE; CYCLOPROPANE; CYCLOPROPANE DERIVATIVE; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; INDAN DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA; PYRROLE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; SYNTHESIS;

CYCLOPROPANES; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; INDANS; PROTEIN KINASE C; PYRROLES; PYRROLIDINES;

EID: 34548157997     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol071336h     Document Type: Article

References (49)

1. (a) Tanaka, M.; Sagawa, S.; Hoshi, J.; Shimoma, F.; Yasue, K.; Ubukata, M.; Ikemoto, T.; Hase, Y.; Takahashi, M.; Sasase, T.; Ueda, N.; Matsushita, M.; Inaba, T. Bioorg. Med. Chem. 2006, 14, 5781-5794.
2. (b) Sasase, T.; Yamada, H.; Sakoda, K.; Imagawa, N.; Abe, T.; Ito, M.; Sagawa, S.; Tanaka, M.; Matsushita, M. Diabetes Obes. Metab. 2005, 7, 586-594.
3. (a) Alper, P. B.; Meyers, C.; Lerchner, A.; Siegel, D. R.; Carreira, E. M. Angew. Chem., Int. Ed. 1999, 38, 3186-3189.
4. (b) Fischer, C.; Meyers, C.; Carreira, E. M. Helv. Chim. Acta 2000, 83, 1175-1181.
5. (c) Lerchner, A.; Carreira, E. M. J. Am. Chem. Soc. 2002, 124, 14826-14827.
6. (d) Meyers, C.; Carreira, E. M. Angew. Chem., Int. Ed. 2003, 42, 694-696.
7. (e) Saigo, K.; Shimada, S.; Hasegawa, M. Chem. Lett. 1990, 905-908.
8. (f) Bertozzi, F.; Gustafsson, M.; Olsson, R. Org. Lett. 2002, 4, 3147-3150.
9. (g) Christie, S. D. R.; Davoile, R. J.; Jones, R. C. F. Org. Biomol. Chem. 2006, 4, 2683-2684.
10. (h) Yamago, S.; Yanagawa, M.; Nakamura, E. Chem. Lett. 1999, 879-880.
11. (i) Oh, B. H.; Nakamura, I.; Saito, S.; Yamamoto, Y. Tetrahedron Lett. 2001, 42, 6203-6205.
12. (j) Lautens, M.; Han, W. J. Am. Chem. Soc. 2002, 124, 6312-6316.
13. (k) Scott, M. E.; Han, W.; Lautens, M. Org. Lett. 2004, 6, 3309-3312.
14. (l) Taillier, C.; Lautens, M. Org. Lett. 2007, 9, 591-593.
15. (m) Carson, C. A.; Kerr, M. A. J. Org. Chem. 2005, 70, 8242-8244.
16. Patient, L.; Berry, M. B.; Coles, S. J.; Hursthouse, M. B.; Kilburn, J. D. Chem. Commun. 2003, 2552-2553.
17. Yamamoto, K.; Ishida, T.; Tsuji, J. Chem. Lett. 1987, 1157-1158.
18. Homo [3 + 2] dipolar cycloaddition: (a) Young, I. S.; Williams, J. L.; Kerr, M. A. Org. Lett. 2005, 7, 953-955.
19. (b) Lebold, T. P.; Carson, C. A.; Kerr, M. A. Synlett 2006, 364-368.
20. (c) Sibi, M. P.; Ma, Z.; Jasperse, C. P. J. Am. Chem. Soc 2005, 127, 5764-5765.
21. Yu, M.; Pagenkopf, B. L. J. Am. Chem. Soc 2003, 125, 8122-8123.
22. Morra, N. A.; Morales, C. L.; Bajtos, B.; Wang, X.; Jang, H.; Wang, J.; Yu, M.; Pagenkopf, B. L. Adv. Synth. Catal. 2006, 348, 2385-2390.
23. The asymmetric Rh-catalyzed 1-allylindole C(2)-H bond activation has recently been applied successfully to the synthesis of a JTT-010 analogue. (a) For Rh-catalyzed C(2)-H bond activation of 1-allylindoles, see: Thalji, R. K.; Ellman, J. A.; Bergman, R. G. J. Am. Chem. Soc. 2004, 126, 7192-7193.
24. Thalji, R. K.; Ahrendt, K. A.; Bergman, R. G.; Ellman, J. A. J. Org. Chem. 2005, 70, 6775-6781.
25. (b) Wilson, R. M.; Thalji, R. K.; Bergman, R. G.; Ellman, J. A. Org. Lett. 2006, 8, 1745-1747.
26. Compound 2b was prepared from (R)-epichlorohydrin and diethyl malonate via one step. See: Sekiyama, T.; Hatsuya, S.; Tanaka, Y.; Uchiyama, M.; Ono, N.; Iwayama, S.; Oikawa, M.; Suzuki, K.; Okunishi, M.; Tsuji, T. J. Med. Chem. 1998, 41, 1284-1298.
27. See Supporting Information for X-ray crystallographic data of 7. Oxidation of 7 followed by methyl esterification gave 9, defining the absolute configuration of 7 as depicted because 9 was also obtained from 8a, whose absolute configuration was authenticated by its conversion to JTT-010.
28. (a) Moody, C. J.; Norton, C. L.; Slawin, A. M. Z.; Taylor, S. Anti-Cancer Drug Des. 1998, 13, 611-634. Also see references cited therein.
29. (b) Naylor, M. A.; Jaffar, M.; Nolan, J.; Stephens, M. A.; Butler, S.; Patel, K. B.; Everett, S. A.; Adams, G. E.; Stratford, I. J. J. Med. Chem. 1997, 40, 2335-2346. Also see references cited therein.
30. (c) Gensini, M.; de Meijere, A. Chem. Eur. J. 2004, 10, 785-790.
31. Another reaction pathway involving nucleophilic attack at the methylene of 2b followed by decarboxylation and cyclization was ruled out since this pathway should not provide 7 but the enantiomer of 7.
32. Compound If was prepared in one step from 2-oxindole. See the Supporting Information.
33. Unpurified 2b was used in this 100 g scale reaction batch.
34. (a) For decarboxylation of an indole-2-acetic acid derivative, see: Ho, B. T.; Walker, K. E. Org. Synth. 1988, VI, 965-966.
35. (b) For decarboxylation of indole-3-carboxylic acid, see: Challis, B. C.; Rzepa, H. S. J. Chem. Soc., Perkin Trans. 2 1977, 281-286.
36. (c) In this case, iterative operation was required to complete the reaction because partial lactone regeneration was competitive with the decarboxylation under acidic conditions.
37. One of the minor isomers isolated from products of a chiral nitrone cycloaddition reaction was reportedly transformed into 10 (∼1% overall yield). Beccalli, E. M.; Broggini, G.; Rosa, C. L.; Passarella, D.; Pilati, T.; Terraneo, A.; Zecchi, G. J. Org. Chem. 2000, 65, 8924-8932.
38. (a) Degener, E.; Schmelzer, H. G.; Frohberger, P. F. Br. Patent 1145583, Mar 19, 1969.
39. (b) Chem. Abstr. 1969, 70, 114648t.
40. Bit, R. A.; Davis, P. D.; Elliott, L. H.; Harris, W.; Hill, C. H.; Keech, E.; Kumar, H.; Lawton, G.; Maw, A.; Nixon, J. S.; Vesey, D. R.; Wadsworth, J.; Wilkinson. S. E. J. Med. Chem. 1993, 36, 21-29.
41. (a) Gervais, F. G.; Morello, J.-P.; Beaulieu, C.; Sawyer, N.; Denis, D.; Greig, G.; Malebranche, A. D.; O'Neill, G. P. Mol. Pharmacol. 2005, 67, 1834-1839.
42. (b) Wang, Z.; Dufresne, C.; Guay, D.; Leblanc, Y. Int. Pat. Appl. WO 02/094830 A2, Nov 28, 2002.
43. (a) Bentley, J. M.; Bickerdike, M. J.; Hebeisen, P.; Kennett, G. A.; Lightowler, S.; Mattei, P.; Mizrahi, J.; Morley, T. J.; Plancher, J.-M.; Richter, H.; Roever, S.; Taylor, S.; Vickers, S. P. Int. Pat. Appl. WO 02/051844 A1, July 4, 2002.
44. (b) Adams, D. R.; Bentley, J. M.; Roffey, J. R. A.; Hamlyn, R. J.; Gaur, S.; Duncton, M. A. J.; Davidson, J. E. P.; Bickerdike, M. J.; Cliffe, I. A.; Mansell, H. L. Int. Pat. Appl. WO 00/12510, Mar 9, 2000.
45. (c) Peters, R.; Waldmeier, P.; Joncour, A. Org. Process Res. Dev. 2005, 9, 508-512.
46. (a) Utsunomiya, I.; Muratake, H.; Natsume, M. Chem. Pharm. Bull. 1995, 43, 37-48.
47. (b) Danishefsky, S. J.; Schkeryantz, J. M. Synlett 1995, 475-490.
48. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Bioorg. Med. Chem. 1997, 5, 49-64. Also see references cited therein.
49. Suleman, A.; Skibo, E. B. J. Med. Chem. 2002, 45, 1211-1220.